Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALPL | P05186 | 1/20 | 0.58 |
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | ALPG | P10696 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | PLEC | Q15149 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 15/20 | 0.54 |
| ▸ | CA1 | P00915 | 13/20 | 0.54 |
| ▸ | CA2 | P00918 | 13/20 | 0.54 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22651493 | 0.89 | USP2 (0.68) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL16283416 | 0.88 | USP2 (0.67) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL18897669 | 0.85 | USP2 (0.62) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL12134945 | 0.83 | USP2 (0.60) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL1437042 | 0.83 | USP2 (0.78) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL20254033 | 0.82 | USP2 (0.77) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL12657220 | 0.82 | CA9 (0.58) | USP2L3MBTL1CA9CA1CA2 | |
| SCHEMBL10098714 | 0.82 | USP2 (0.76) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL30023431 | 0.82 | USP2 (1.00) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL3481432 | 0.82 | USP2 (1.00) | USP2L3MBTL1MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793947-B1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2021-02-03 | — | — | EP | disclosed |
| US-10675359-B2 | Enzymatic conjugation of antibodies | INNATE PHARMA (FR) | 2020-06-09 | — | — | US | disclosed |
| EP-3564259-A2 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | Innate Pharma (FR) | 2019-11-06 | — | — | EP | disclosed |
| US-10434180-B2 | Enzymatic conjugation of polypeptides | INNATE PHARMA (FR) | 2019-10-08 | — | — | US | disclosed |
| US-20190169601-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | INNATE PHARMA (FR) | 2019-06-06 | — | — | US | disclosed |
| EP-2872894-B1 | SCREENING OF CONJUGATED ANTIBODIES | INNATE PHARMA (FR) | 2019-04-17 | — | — | EP | disclosed |
| EP-3240573-B1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2019-03-20 | — | — | EP | disclosed |
| US-10132799-B2 | Screening of conjugated antibodies | INNATE PHARMA (FR) | 2018-11-20 | — | — | US | disclosed |
| EP-2793949-B1 | ENZYMATIC CONJUGATION OF ANTIBODIES | INNATE PHARMA (FR) | 2018-08-22 | — | — | EP | disclosed |
| US-10036010-B2 | Recognition tags for TGase-mediated conjugation | INNATE PHARMA (FR) | 2018-07-31 | — | — | US | disclosed |
| US-20090118471-A1 | NOVEL COUMARIN DERIVATIVES | THE UNIVERSITY OF TOKYO (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7482473-B2 | Coumarin derivative | THE UNIVERSITY OF TOKYO (JP) | 2009-01-27 | — | — | US | disclosed |
| US-7482473-B2 | Coumarin derivative | THE UNIVERSITY OF TOKYO (JP) | 2009-01-27 | — | — | US | disclosed |
| US-7465814-B2 | Sulfonate compound and fluorescent probe using the same | OSAKA INDUSTRIAL PROMOTION ORGANIZATION (JP) | 2008-12-16 | — | — | US | disclosed |
| US-7465814-B2 | Sulfonate compound and fluorescent probe using the same | OSAKA INDUSTRIAL PROMOTION ORGANIZATION (JP) | 2008-12-16 | — | — | US | disclosed |
| US-7387771-B1 | dissolving in carrier liquid; drug linked to a protein-binding molecule via a spacer which is cleaved hydrolytically or enzymatically in the body of a subject in a pH-dependent manner; tissue targeted delivery; Doxorubicin-phenylacetylhydrazone spacer-maleimide | KTB TUMORFORSCHUNGS GMBH (DE) | 2008-06-17 | — | — | US | disclosed |
| US-7387771-B1 | dissolving in carrier liquid; drug linked to a protein-binding molecule via a spacer which is cleaved hydrolytically or enzymatically in the body of a subject in a pH-dependent manner; tissue targeted delivery; Doxorubicin-phenylacetylhydrazone spacer-maleimide | KTB TUMORFORSCHUNGS GMBH (DE) | 2008-06-17 | — | — | US | disclosed |
| US-7273920-B2 | Controlling protein levels in eucaryotic organisms | WELLSTAT BIOCATALYSIS, LLC (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070197778-A1 | NOVEL COUMARIN DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197778-A1 | NOVEL COUMARIN DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675359-B2 | Enzymatic conjugation of antibodies | DNPEP, MPO, FCGR3B | USP2 862/4885L3MBTL1 4099/4885MEN1 4673/4885 |
| US-10434180-B2 | Enzymatic conjugation of polypeptides | DNPEP, ENPEP, PEPD | USP2 841/4885L3MBTL1 3802/4885MEN1 4381/4885 |
| US-10132799-B2 | Screening of conjugated antibodies | FCGR2A, TGM2, TGM6 | USP2 1063/4885L3MBTL1 1313/4885MEN1 4063/4885 |
| US-10036010-B2 | Recognition tags for TGase-mediated conjugation | TGM2, TGM3, TGM6 | USP2 1141/4885L3MBTL1 1846/4885MEN1 3810/4885 |
| US-20090118471-A1 | NOVEL COUMARIN DERIVATIVES | CBR3, MRPS23, MRPS22 | USP2 4295/4885L3MBTL1 1586/4885MEN1 451/4885 |
| US-20190169601-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | TGM2, TGM3, TGM6 | USP2 1141/4885L3MBTL1 1846/4885MEN1 3810/4885 |
| US-20070197778-A1 | NOVEL COUMARIN DERIVATIVE | CBR3, MRPS22, MRPS23 | USP2 4282/4885L3MBTL1 1562/4885MEN1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.